Broad Institute, IBM Watson launch initiative to study cancer drug resistance

IBM Watson Health (NYSE:IBM) and the Broad Institute said today that they’ve launched a research initiative with the hopes of discovering the basis for cancer drug resistance.

The 5 year, $50 million collaboration will study the genetic information of thousands of drug resistant tumors and use Watson’s machine learning methods to help understand the underlying mechanisms that drive cancer drug resistance. The resulting data will be made available to scientific community, according to the group.

Get the full story at our sister site, Drug Delivery Business News.

The post Broad Institute, IBM Watson launch initiative to study cancer drug resistance appeared first on MassDevice.

from MassDevice http://www.massdevice.com/broad-institute-ibm-watson-launch-initiative-study-cancer-drug-resistance/